Aptamer Oligonucleotides as Potential Therapeutics in Hematologic Diseases

Area of Science:

• Biotechnology
• Molecular Biology
• Hematology

Background:

• Aptamers are nucleic acid-based therapeutics selected through Systematic evolution of ligands by exponential enrichment (SELEX).
• Over the last 20 years, aptamer development has led to numerous drug candidates entering clinical trials.
• Hematological diseases represent a significant area for aptamer therapeutic application.

Purpose of the Study:

• To review the therapeutic potential of aptamers for various hematological diseases.
• To highlight aptamer drug candidates that have progressed into clinical trials.
• To focus on specific blood disorders including anemia, hemophilia, TTP, and sickle cell disease.

Main Methods:

• Literature review of aptamer development and clinical trial data.
• Focus on aptamers selected via SELEX for hematological targets.
• Analysis of aptamer applications in anemia of chronic inflammation (ACI), anemia of chronic disease (ACD), hemophilia, thrombotic thrombocytopenic purpura (TTP), VWD type-2B, and sickle cell disease (SCD).

Main Results:

• Aptamers have demonstrated promise as therapeutics for several hematological conditions.
• Multiple aptamer-based drugs are currently undergoing clinical evaluation.
• Specific aptamers are being investigated for ACI, ACD, hemophilia, TTP/VWD type-2B, and SCD.

Conclusions:

• Aptamers are a viable therapeutic strategy for hematological diseases.
• The progression of aptamer drugs into clinical trials underscores their therapeutic potential.
• Further research and clinical development are warranted for aptamer-based treatments in hematology.